Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant versus hydroxyzine for persistent aquagenic pruritus in myeloproliferative neoplasms
2018-000426-66Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of aprepitant and hydroxyzine in Aquagenic pruritus (AP) (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Primary efficacy endpoint. Started May 2018; status: completed.
02
Drugs
aprepitanthydroxyzine
03
Conditions
Aquagenic pruritus (AP)
Beyond the preview
Go deeper on 2018-000426-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000426-66.